Cancer markers in patients receiving chemotherapy for colorectal cancer: A preliminary report
The combination of CEA, hepatic function marker enzymes, and four acute phase reactant proteins (haptoglobin, α1 antitrypsin, α1 acid glycoprotein, and prealbumin) has been used to monitor patients with colorectal cancer receiving chemotherapy. In 18 patients with advanced lesions who survived at le...
Gespeichert in:
| Veröffentlicht in: | Medical and pediatric oncology 1977, Vol.3 (3), p.289-300 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 300 |
|---|---|
| container_issue | 3 |
| container_start_page | 289 |
| container_title | Medical and pediatric oncology |
| container_volume | 3 |
| creator | Bullen, B. R. Cooper, E. H. Turner, R. Neville, A. M. Giles, G. R. Hall, R. |
| description | The combination of CEA, hepatic function marker enzymes, and four acute phase reactant proteins (haptoglobin, α1 antitrypsin, α1 acid glycoprotein, and prealbumin) has been used to monitor patients with colorectal cancer receiving chemotherapy.
In 18 patients with advanced lesions who survived at least 3 months treatment the markers predicted progression in 92% of 25 incidents of progression; the mean lead time was 2.8 months. A rising CEA was only present in 28%, but in these patients it gave a mean lead time of 4 months. In the group of 14 patients with minimal residual disease progression to clinically detectable disease has occurred in 9 of them. In these cases the markers predicted progression with a mean lead time of 6 months; in a further six patients the markers have indicated progression, but as yet their disease is not detectable, the mean lead time being at least 8.6 months. CEA and the liver enzyme markers are the most sensitive indicators of progression of the minimal residual disease group. |
| doi_str_mv | 10.1002/mpo.2950030311 |
| format | Article |
| fullrecord | <record><control><sourceid>istex_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_mpo_2950030311</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ark_67375_WNG_LV303RPM_C</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3451-6aa1fc004073c44a8bbe7103b95a5dc3f9cbfccbe7fee472f60ab27294cdc5d53</originalsourceid><addsrcrecordid>eNqFkMtOwzAQRS1EBaWwZcPGP5AyjuMkZldVUJBaWiFeG2Q5jkMNeckJj_w9pkFFrFiNPHfOlXwQOiYwJgD-aVFXY58zAAqUkB00JMBDjxPyuIuGADz2CKP-Pjpomhdwbx7Fe2hAA4jZED1NZam0xYW0r9o22JS4lq3RZdtgq5U276Z8xmqti6pdayvrDmeVxarKKxe3MsdqU3CGJ7i2OjeFKaXtHFtXtj1Eg0zmjT76mSN0d3F-O7305svZ1XQy9xQNGPFCKUmmAAKIqAoCGSeJjgjQhDPJUkUzrpJMKbfMtA4iPwtBJn7k80CliqWMjtC471W2ahqrM1Fb477UCQLiW5JwksSvJAec9ED9lhQ63Z5vrLiU9-mHyXX3T5dYrJZ_mr2eNU2rP7es0yvCiEZMPFzPxPzeHd-sFmJKvwBM9ITE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Cancer markers in patients receiving chemotherapy for colorectal cancer: A preliminary report</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Bullen, B. R. ; Cooper, E. H. ; Turner, R. ; Neville, A. M. ; Giles, G. R. ; Hall, R.</creator><creatorcontrib>Bullen, B. R. ; Cooper, E. H. ; Turner, R. ; Neville, A. M. ; Giles, G. R. ; Hall, R.</creatorcontrib><description>The combination of CEA, hepatic function marker enzymes, and four acute phase reactant proteins (haptoglobin, α1 antitrypsin, α1 acid glycoprotein, and prealbumin) has been used to monitor patients with colorectal cancer receiving chemotherapy.
In 18 patients with advanced lesions who survived at least 3 months treatment the markers predicted progression in 92% of 25 incidents of progression; the mean lead time was 2.8 months. A rising CEA was only present in 28%, but in these patients it gave a mean lead time of 4 months. In the group of 14 patients with minimal residual disease progression to clinically detectable disease has occurred in 9 of them. In these cases the markers predicted progression with a mean lead time of 6 months; in a further six patients the markers have indicated progression, but as yet their disease is not detectable, the mean lead time being at least 8.6 months. CEA and the liver enzyme markers are the most sensitive indicators of progression of the minimal residual disease group.</description><identifier>ISSN: 0098-1532</identifier><identifier>EISSN: 1096-911X</identifier><identifier>DOI: 10.1002/mpo.2950030311</identifier><identifier>PMID: 34085</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>acute phase reactant protein ; Alkaline Phosphatase - blood ; alpha 1-Antitrypsin - analysis ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - therapeutic use ; Blood Proteins - analysis ; Carcinoembryonic Antigen - analysis ; CEA ; chemotherapy monitoring ; Colonic Neoplasms - diagnosis ; Colonic Neoplasms - drug therapy ; Colonic Neoplasms - mortality ; colorectal cancer ; gamma-Glutamyltransferase - blood ; Glycoproteins - blood ; Haptoglobins - analysis ; Humans ; Nucleotidases - blood ; Prealbumin - analysis ; Rectal Neoplasms - diagnosis ; Rectal Neoplasms - drug therapy ; Rectal Neoplasms - mortality</subject><ispartof>Medical and pediatric oncology, 1977, Vol.3 (3), p.289-300</ispartof><rights>Copyright © 1977 Wiley‐Liss, Inc., A Wiley Company</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3451-6aa1fc004073c44a8bbe7103b95a5dc3f9cbfccbe7fee472f60ab27294cdc5d53</citedby><cites>FETCH-LOGICAL-c3451-6aa1fc004073c44a8bbe7103b95a5dc3f9cbfccbe7fee472f60ab27294cdc5d53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fmpo.2950030311$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fmpo.2950030311$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,4010,27904,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34085$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bullen, B. R.</creatorcontrib><creatorcontrib>Cooper, E. H.</creatorcontrib><creatorcontrib>Turner, R.</creatorcontrib><creatorcontrib>Neville, A. M.</creatorcontrib><creatorcontrib>Giles, G. R.</creatorcontrib><creatorcontrib>Hall, R.</creatorcontrib><title>Cancer markers in patients receiving chemotherapy for colorectal cancer: A preliminary report</title><title>Medical and pediatric oncology</title><addtitle>Med. Pediatr. Oncol</addtitle><description>The combination of CEA, hepatic function marker enzymes, and four acute phase reactant proteins (haptoglobin, α1 antitrypsin, α1 acid glycoprotein, and prealbumin) has been used to monitor patients with colorectal cancer receiving chemotherapy.
In 18 patients with advanced lesions who survived at least 3 months treatment the markers predicted progression in 92% of 25 incidents of progression; the mean lead time was 2.8 months. A rising CEA was only present in 28%, but in these patients it gave a mean lead time of 4 months. In the group of 14 patients with minimal residual disease progression to clinically detectable disease has occurred in 9 of them. In these cases the markers predicted progression with a mean lead time of 6 months; in a further six patients the markers have indicated progression, but as yet their disease is not detectable, the mean lead time being at least 8.6 months. CEA and the liver enzyme markers are the most sensitive indicators of progression of the minimal residual disease group.</description><subject>acute phase reactant protein</subject><subject>Alkaline Phosphatase - blood</subject><subject>alpha 1-Antitrypsin - analysis</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Blood Proteins - analysis</subject><subject>Carcinoembryonic Antigen - analysis</subject><subject>CEA</subject><subject>chemotherapy monitoring</subject><subject>Colonic Neoplasms - diagnosis</subject><subject>Colonic Neoplasms - drug therapy</subject><subject>Colonic Neoplasms - mortality</subject><subject>colorectal cancer</subject><subject>gamma-Glutamyltransferase - blood</subject><subject>Glycoproteins - blood</subject><subject>Haptoglobins - analysis</subject><subject>Humans</subject><subject>Nucleotidases - blood</subject><subject>Prealbumin - analysis</subject><subject>Rectal Neoplasms - diagnosis</subject><subject>Rectal Neoplasms - drug therapy</subject><subject>Rectal Neoplasms - mortality</subject><issn>0098-1532</issn><issn>1096-911X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1977</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtOwzAQRS1EBaWwZcPGP5AyjuMkZldVUJBaWiFeG2Q5jkMNeckJj_w9pkFFrFiNPHfOlXwQOiYwJgD-aVFXY58zAAqUkB00JMBDjxPyuIuGADz2CKP-Pjpomhdwbx7Fe2hAA4jZED1NZam0xYW0r9o22JS4lq3RZdtgq5U276Z8xmqti6pdayvrDmeVxarKKxe3MsdqU3CGJ7i2OjeFKaXtHFtXtj1Eg0zmjT76mSN0d3F-O7305svZ1XQy9xQNGPFCKUmmAAKIqAoCGSeJjgjQhDPJUkUzrpJMKbfMtA4iPwtBJn7k80CliqWMjtC471W2ahqrM1Fb477UCQLiW5JwksSvJAec9ED9lhQ63Z5vrLiU9-mHyXX3T5dYrJZ_mr2eNU2rP7es0yvCiEZMPFzPxPzeHd-sFmJKvwBM9ITE</recordid><startdate>1977</startdate><enddate>1977</enddate><creator>Bullen, B. R.</creator><creator>Cooper, E. H.</creator><creator>Turner, R.</creator><creator>Neville, A. M.</creator><creator>Giles, G. R.</creator><creator>Hall, R.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>1977</creationdate><title>Cancer markers in patients receiving chemotherapy for colorectal cancer: A preliminary report</title><author>Bullen, B. R. ; Cooper, E. H. ; Turner, R. ; Neville, A. M. ; Giles, G. R. ; Hall, R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3451-6aa1fc004073c44a8bbe7103b95a5dc3f9cbfccbe7fee472f60ab27294cdc5d53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1977</creationdate><topic>acute phase reactant protein</topic><topic>Alkaline Phosphatase - blood</topic><topic>alpha 1-Antitrypsin - analysis</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Blood Proteins - analysis</topic><topic>Carcinoembryonic Antigen - analysis</topic><topic>CEA</topic><topic>chemotherapy monitoring</topic><topic>Colonic Neoplasms - diagnosis</topic><topic>Colonic Neoplasms - drug therapy</topic><topic>Colonic Neoplasms - mortality</topic><topic>colorectal cancer</topic><topic>gamma-Glutamyltransferase - blood</topic><topic>Glycoproteins - blood</topic><topic>Haptoglobins - analysis</topic><topic>Humans</topic><topic>Nucleotidases - blood</topic><topic>Prealbumin - analysis</topic><topic>Rectal Neoplasms - diagnosis</topic><topic>Rectal Neoplasms - drug therapy</topic><topic>Rectal Neoplasms - mortality</topic><toplevel>online_resources</toplevel><creatorcontrib>Bullen, B. R.</creatorcontrib><creatorcontrib>Cooper, E. H.</creatorcontrib><creatorcontrib>Turner, R.</creatorcontrib><creatorcontrib>Neville, A. M.</creatorcontrib><creatorcontrib>Giles, G. R.</creatorcontrib><creatorcontrib>Hall, R.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Medical and pediatric oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bullen, B. R.</au><au>Cooper, E. H.</au><au>Turner, R.</au><au>Neville, A. M.</au><au>Giles, G. R.</au><au>Hall, R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cancer markers in patients receiving chemotherapy for colorectal cancer: A preliminary report</atitle><jtitle>Medical and pediatric oncology</jtitle><addtitle>Med. Pediatr. Oncol</addtitle><date>1977</date><risdate>1977</risdate><volume>3</volume><issue>3</issue><spage>289</spage><epage>300</epage><pages>289-300</pages><issn>0098-1532</issn><eissn>1096-911X</eissn><abstract>The combination of CEA, hepatic function marker enzymes, and four acute phase reactant proteins (haptoglobin, α1 antitrypsin, α1 acid glycoprotein, and prealbumin) has been used to monitor patients with colorectal cancer receiving chemotherapy.
In 18 patients with advanced lesions who survived at least 3 months treatment the markers predicted progression in 92% of 25 incidents of progression; the mean lead time was 2.8 months. A rising CEA was only present in 28%, but in these patients it gave a mean lead time of 4 months. In the group of 14 patients with minimal residual disease progression to clinically detectable disease has occurred in 9 of them. In these cases the markers predicted progression with a mean lead time of 6 months; in a further six patients the markers have indicated progression, but as yet their disease is not detectable, the mean lead time being at least 8.6 months. CEA and the liver enzyme markers are the most sensitive indicators of progression of the minimal residual disease group.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>34085</pmid><doi>10.1002/mpo.2950030311</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0098-1532 |
| ispartof | Medical and pediatric oncology, 1977, Vol.3 (3), p.289-300 |
| issn | 0098-1532 1096-911X |
| language | eng |
| recordid | cdi_crossref_primary_10_1002_mpo_2950030311 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | acute phase reactant protein Alkaline Phosphatase - blood alpha 1-Antitrypsin - analysis Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use Blood Proteins - analysis Carcinoembryonic Antigen - analysis CEA chemotherapy monitoring Colonic Neoplasms - diagnosis Colonic Neoplasms - drug therapy Colonic Neoplasms - mortality colorectal cancer gamma-Glutamyltransferase - blood Glycoproteins - blood Haptoglobins - analysis Humans Nucleotidases - blood Prealbumin - analysis Rectal Neoplasms - diagnosis Rectal Neoplasms - drug therapy Rectal Neoplasms - mortality |
| title | Cancer markers in patients receiving chemotherapy for colorectal cancer: A preliminary report |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T08%3A26%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-istex_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cancer%20markers%20in%20patients%20receiving%20chemotherapy%20for%20colorectal%20cancer:%20A%20preliminary%20report&rft.jtitle=Medical%20and%20pediatric%20oncology&rft.au=Bullen,%20B.%20R.&rft.date=1977&rft.volume=3&rft.issue=3&rft.spage=289&rft.epage=300&rft.pages=289-300&rft.issn=0098-1532&rft.eissn=1096-911X&rft_id=info:doi/10.1002/mpo.2950030311&rft_dat=%3Cistex_cross%3Eark_67375_WNG_LV303RPM_C%3C/istex_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/34085&rfr_iscdi=true |